Endocrinology

The treatment reduced UACR by 37.1% and LDLc by 17.12 compared to placebo.

Data from the STEP TEENS trial, which assessed the benefits of semaglutide 2.4 mg (Wegovy) in individuals aged 12-18 years with overweight or obesity, indicates use of the GLP-1 receptor agonist was associated with a mean reduction in body weight of 16% during the 68-week trial.

Published on November 1, the USPSTF reaffirmed their stance against use of hormone therapy for primary prevention of chronic conditions in postmenopausal persons, which was the stance the organization took in their 2017 recommendations.

The October 2022 month in review recap includes a pair of studies that paint a grim picture related to the burden of diabetes in the US, a trio of new obesity guidelines/reports from major national and international organizations, and news related to the latest developments in the world of continuous glucose monitoring.

An analysis of patient data from people with type 1 diabetes using flash glucose monitoring suggests increased scanning frequency could improve glycemic control and reduce fear of hypoglycemia in people using intermittently scanned continuous glucose monitoring.

Welcome back to Crisis Point. A special episode focuses on the issue of insulin accessibility and affordability in the United States, with four experts in the diabetes arena weighing in on the topic.

In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the ongoing GLP-1 RA shortage and whether or not celebrities using these agents for weight loss is a real issue in the community as well as provide insight into their top takeaways from the ADA/KDIGO consensus report.

Published on October 21, the metabolic and bariatric surgery guideline considerations from the American Society of Metabolic and Bariatric Surgery and the International Federation for the Surgery of Obesity and Metabolic Disorders represent the first major updates to guidance since a National Institutes of Health document released in 1991.

Released on October 21, the special joint report from the Obesity Society and National Kidney Foundation outlines the hurdles, optimization strategies, and research needs for the management of coexisiting obesity and chronic kidney disease identified during a multispecialty, scientific workshop held in April 2021.

Released on October 20, the American Gastroenterological Association's guidelines for obesity management with pharmacological therapy endorses semaglutide 2.4 mg (Wegovy), phentermine-topiramate ER (Qsymia), lirgalutide 3 mg (Saxenda), and naltrexone-bupropion ER (Contrave) as first-line medical therapies in addition to diet and exercise for weight loss in people with obesity.

National coverage of MTMs for diet-related diseases may be associated with 1.6 million averted hospitalizations and net cost savings of $13.6 billion annually.

Top-line data comparing 2 strains of a non-systemically absorbed drug candidate was announced this morning, with SYNB1934 expected to advance to a phase 3 clinical trial.

The emergence of weight loss agents like tirzepatide and an FDA Fast Track designation announced days earlier, endocrinologists were excited to discuss what's happening at Pri-Med Midwest 2022.

As the age of diagnosis for pre and type 2 diabetes continues to decrease, Dr. Tina Thethi believes in focusing on reducing risk factors to prevent further complications.

The glycemic gap was a stronger predictor of in-hospital mortality among adults with diabetes or hyperglycemia hospitalized for COVID-19.

In this special edition episode of Diabetes Dialogue, our hosts break down their top clinical takeaways from the European Association for the Study of Diabetes 2022 annual meeting, new data from the FLASH-UK trial, the global launch of Dexcom G7, and the announcement of US availability for the FreeStyle Libre 3.

Daily administration of AZP-3601 enabled 93% of patients to discontinue standard of care therapy and maintain target mean serum calcium.

Data from the FLASH-UK trial, which compared FreeStyle Libre 2 against usual care for glycemic control in type 1 diabetes, provide evidence demonstrating improved glycemic control and time in target glucose range among users of the FreeStyle Libre 2 system.

Both drug classes would improve type 2 diabetes outcomes as first-line agents, but costs would be need to be reduced by at least 70% to be considered cost-effective.

Released on October 6, the joint consensus report from the ADA and EASD provides an overview of the benefits and safety concerns related to AID systems as well as offering a multitude of evidence-based recommendations on the subject.

Greater psychological resilience was associated with lower BMI, fewer hospitalizations, and greater mental QOL in the T2D population.

On October 4, the Endocrine Society announced the release of a 10-page policy perspective outlining guidance related to optimal use of telehealth in endocrine care, which was composed by a 9-member panel led by Varsha G. Vimalananda, MD, MPH.

Dexcom announced their Dexcom G7 CGM system is now available for people aged 2 years or older in the UK, Ireland, Germany, Austria, and Hong Kong beginning on October 4, with plans for a rollout in New Zealand and South Africa.

100 years after the discovery of insulin, the T1D Index may provide a foundational understanding of what steps need to be taken to both improve lives and reduce the incidence of T1D.

With the launch of the T1D index, the global burden of the disease and its impact is better understood. Dr. Kowalski joins to dig deeper into its importance and his personal connection to T1D.

In this regularly scheduled September 2022 episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, provide their own perspective on DIY looping based on the results of a recent study published in the New England Journal of Medicine and also break down a new set of consensus recommendations for the use of automated insulin delivery (AID) systems in clinical practice published in Endocrine Reviews, which Isaacs helped compose as a member of the writing committee.

Our latest endocrine case report from Brady Pregerson, MD, features a person in their mid-70s with a history of obesity, hypertension, osteoporosis, and prior ankle surgery presenting to urgent care with right lateral foot pain ongoing for about 10 days. Can you determine the correct diagnosis?

Our endocrinology month in review spotlights the most popular content from the past month. Our top content from September 2022 includes new guideline recommendations from the ADA/EASD, new data on semaglutide 2.4 mg and tirzepatide, a label update for finerenone, & more!

Diabetes mortality rates in 2017-2018 compared with 1999-2000 were highest and unchanged in rural counties.

Announced on September 20, the alerts from the FDA and Medtronic notify users of a potential cybersecurity risk identified through internal testing at Medtronic that would allow unauthorized users to the pump's communication protocol, which could allow unauthorized boluses.